Long-term complications of chemotherapy for germ cell tumours

Drugs

Volumn 63, Issue 15, 2003, Pages 1565-1577

  Chaudhary, Uzair B ^a   Haldas, Jason R ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN;

CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; GERM CELL TUMOR; HEART INFARCTION; HUMAN; INFERTILITY; LEUKEMIA; LUNG TOXICITY; NEPHROTOXICITY; NEUROTOXICITY; OTOTOXICITY; RAYNAUD PHENOMENON; REVIEW; SOLID TUMOR; VASCULAR DISEASE;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS; DOSE-RESPONSE RELATIONSHIP, DRUG; GERMINOMA; HUMANS; INFERTILITY; KIDNEY DISEASES; LUNG DISEASES; MALE; NEOPLASMS; PERIPHERAL NERVOUS SYSTEM DISEASES; RISK FACTORS; TESTICULAR NEOPLASMS; TIME FACTORS; VASCULAR DISEASES;

EID: 0042122626     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200363150-00004     Document Type: Review

References (97)

1. Small EJ, Torti FM. Testes. In: Abeloff MD, editor. Clinical oncology. New York: Churchill Livingstone, 1995: 1494
2. Donohue JP, Rowland RG. Complications of retroperitoneal lymph node dissection. J Urol 1981; 125: 338-40
3. Donohue JP, Thornhill JA, Foster RS, et al. The role of retroperitoneal lymphadenectomy in clinical stage B testicular cancer: the Indiana university experience (1965 to 1989). J Urol 1995; 153: 85-9
4. Loehrer PJ, Williams SD, Einhorn LH. Testicular cancer: the quest continues. J Natl Cancer Inst 1988; 80: 1373-82
5. Samuels ML, Lanzotti VJ, Holoye PY, et al. Combination chemotherapy in germinal cell tumors. Cancer Treat Rev 1976; 3: 185-204
6. Einhorn LH, Donohue J. Cis-diamminedichloroplatinum, vinlastine, and bleomycin combination chemotherapy in disseminated testicular cancer. Ann Intern Med 1977; 87: 293-8
7. Bosl GJ, Gluckman R, Geller NL, et al. VAB-6 an effective chemotherapy regimen for patients with germ cell tumors. J Clin Oncol 1986; 4: 1493-9
8. Fitzharris BM, Kaye SB, Saverymuttu S, et al. VP16-213 as a single agent in advanced testicular tumors. Eur J Cancer 1980; 16: 1193-7
9. Williams SD, Birch R, Einhorn LH, et al. Treatment of disseminated germ-cell tumors with cisplatin, bleomycin and either vinblastine or etoposide. N Engl J Med 1987; 316: 1435-40
10. Baniel J, Foster RS, Rowland RG, et al. Complications of post-chemotherapy retroperitoneal lymph node dissection. J Urol 1995; 153: 979-80
11. Coogan CL, Hejase MJ, Wahle GR, et al. Nerve sparing post-chemotherapy retroperitoneal lymph node dissection for advanced testicular cancer. J Urol 1996; 156: 1656-8
12. International germ cell consensus classification: a prognostic factor-based staging system for metastatic germ cell cancers. J Clin Oncol 1997; 15: 594-603
13. Einhorn LH, Williams SD, Loehrer PJ, et al. Evaluation of optimal duration of chemotherapy in favorable-prognosis disseminated germ cell tumors: a southeastern cancer study group protocol. J Clin Oncol 1989; 7: 387-91
14. Bosl GJ, Geller NL, Bajorin D, et al. A randomized trial of etoposide + cisplatin versus vinblastine + bleomycin + cisplatin + cyclophosphamide + dactinomycin in patients with good prognosis germ cell tumors. J Clin Oncol 1988; 6: 1231-8
15. De Wit R, Wilkinson PM, de Mulder PH, et al. Equivalence of three or four cycles of bleomycin, etoposide, an cisplatin chemotherapy and a 3 or 5-day schedule in good-prognosis germ cell cancer: a randomized study of the European Organization for Research and Treatment of Cancer, Genitourinary Tract Cancer Cooperative Group, and the Medical Research Council. J Clin Oncol 2001; 19: 1629-40
16. Loehrer PJ, Einhorn LH, Williams SD. VP-16 plus ifosfamide plus cisplatin as salvage therapy in refractory germ cell cancer. J Clin Oncol 1986; 4: 528-36
17. Broun ER, Nicholas CR, Gize G, et al. Tandem high dose chemotherapy with autologous bone marrow transplantation for initial relapse of testicular germ cell cancer. Cancer 1997; 79 (8): 1605-1610
18. Mandanas RA, Saez RA, Epstein RB, et al. Long-term results of autologous marrow transplantation for relapsed or refractory male or female germ cell tumors. Bone Marrow Transplant 1998; 21: 569-76
19. Pedersen-Bjergaard J. Therapy-related myelodysplasia and acute leukemia. Leuk Lymphoma 1995; 15: 11-2
20. Bokemeyer C, Schmoll HJ. Secondary neoplasms following treatment of malignant germ cell tumors. J Clin Oncol 1993; 11: 1703-9
21. Kollmannsberger C, Kuzcyk M, Mayer F, et al. Late toxicity following curative treatment of testicular cancer. Semin Surg Oncol 1999; 17: 275-81
22. Ratain MJ, Rowley JD. Therapy-related acute myeloid leukemia secondary to inhibitors of topoisomerase II: from the bedside to the target genes. Ann Oncol 1992; 3: 107-11
23. Bokemeyer C, Freund M, Schmoll HJ, et al. Secondary lymphoblastic leukemia following treatment of a malignant germ cell tumour [letter]. Ann Oncol 1992; 3: 772
24. Travis LB, Holoway EJ, Bergfeldt K, et al. Risk of leukemia after platinum-based chemotherapy for ovarian cancer. N Engl J Med 1999; 340: 351-7
25. Pedersen-Bjergaard J, Daugaard G, Hansen SW, et al. Increased risk of myelodysplasia and leukaemia after etoposide, cisplatin, and bleomycin for germ cell tumours. Lancet 1991; 338 (8763): 359-63
26. Boshoff C, Begent RH, Oliver RT, et al. Secondary tumours following etoposide containing therapy for gem cell cancer. Ann Oncol 1995; 6: 35-40
27. Bajorin DF, Motzer RJ, Rodriguez E, et al. Acute nonlymphocytic leukemia in germ cell tumor patients treated with etoposide-containing chemotherapy. J Natl Cancer Inst 1993; 85: 60-2
28. Nichols CR, Breeden ES, Loehrer PJ, et al. Secondary leukemia associated with a conventional dose of etoposide: review of serial germ cell tumor protocols. J Natl Cancer Inst 1993; 85: 36-40
29. Travis LB, Curtis RE, Storm H, et al. Risk of second malignant neoplasm among long-term survivors of testicular cancer. J Natl Cancer Inst 1997; 89: 1429-39
30. Ayash LJ, Clarke M, Silver SM, et al. Double dose intensive chemotherapy with autologous stem cell support for relapsed or refractory testicular cancer: the University of Michigan experience add literature review. Bone Marrow Transplant 2001; 27: 939-47
31. Pui CH, Ribeiro RC, Hancock ML, et al. Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lymphoblastic leukemia. N Engl J Med 1991; 325: 1682-7
32. Kollmannsberger C, Beyer J, Droz JP, et al. Secondary leukemia following high cummulative doses of etoposide in patients treated for advanced germ cell tumors. J Clin Oncol 1998; 16: 3386-91
33. Kollmannsberger C, Hartmann JT, Kanz L, et al. Risk of secondary myeloid leukemia and myelodysplastic syndrome following standard-dose chemotherapy or high-dose chemotherapy with stem cell support in patients with potentially curable malignancies. J Cancer Res Clin Oncol 1998; 124: 207-14
34. Hartmann JT, Nichols CR, Droz JP, et al. Hematologic disorders associated with primary mediastinal nonseminomatous germ cell tumors. J Natl Cancer Inst 2000; 92: 54-61
35. Nichols CR, Roth BJ, Heerema N, et al. Hematologic neoplasia associated with primary mediastinal germ-cell tumors. N Engl J Med 1990; 322: 1425-9
36. Wanderas EH, Fossa SD, Tretli S. Risk of subsequent non-germ cell cancer after treatment of germ cell cancer in 2006 Norwegian male patients. Eur J Cancer 1997; 33: 253-62
37. Kaldor JM, Day NE, Band P, et al. Second malignancies following testicular cancer, ovarian cancer and Hodgkin's disease: an international collaborative study among cancer registeries. Int J Cancer 1987; 39: 571-85
38. Ginsberg SJ, Comis RL. The pulmonary toxicity of antineoplastic agents. Semin Oncol 1982; 9: 34-51
39. Bauer KA, Skarin AT, Balikian JP, et al. Pulmonary complications associated with combination chemotherapy programs containing bleomycin. Am J Med 1983; 74: 557-63
40. Blom-Muilwijk MC, Vriesendorp R, Veninga TS, et al. Pulmonary toxicity after treatment with bleomycin alone or in combination with hyperoxia. Br J Anaesth 1988; 60: 91-7
41. Hirsch A, Vander Els N, Straus DJ, et al. Effect of ABVD chemotherapy with and without mantle or mediastinal irradiation on pulmonary function and symptoms in early-stage Hodgkin's disease. J Clin Oncol 1996; 14: 1297-305
42. Sleijfer S, Van der Mark TW, Schraffordt Koops H, et al. Enhanced effects of bleomycin on pulmonary function assessments in patients with decreased renal function due to cisplatin. Eur J Cancer 1996; 32A: 550-2
43. Yagoda A, Mukherji B, Young C, et al. Bleomycin: an antitumor antibiotic: clinical experience in 274 patients. Ann Intern Med 1972; 77: 861-70
44. Lower EE, Strohofer S, Baughman RP. Bleomycin causes alveolar macrophages from cigarette smokers to release hydrogen peroxide. Am J Med Sci 1988; 295: 193-7
45. Collis CH. Lung damage of cytotoxic drugs. Cancer Chemother Pharmacol 1980; 4: 17-27
46. Wilson KS, Worth SA, Richards AG, et al. Low-dose bleomycin lung. Med Pediatr Oncol 1982; 10: 283-8
47. Tryka AF, Skomik WA, Godleski JJ, et al. Potentiation of bleomycin-induced lung injury by exposure to 70% oxygen. Am Rev Respir Dis 1982; 126: 1074-6
48. Donat SM, Levy DA. Bleomycin associated pulmonary toxicity: is perioperative oxygen restriction necessary? J Urol 1998; 160: 1347-52
49. White DA, Stover DE. Severe bleomycin-induced pneumonitis: clinical features and response to corticosteroids. Chest 1984; 86: 723-8
50. Comis RL. Detecting bleomycin pulmonary toxicity: a continued conundrum. J Clin Oncol 1990; 8: 765-7
51. Sleijfer S, Van der Mark TW, Schraffordt Koops H, et al. Decrease in pulmonary function during bleomycin-containing combination chemotherapy for testicular cancer: not only a bleomycin effect. Br J Cancer 1995; 71: 120-3
52. Maher J, Daley PA. Severe bleomycin lung toxicity: reversal with high dose corticosteroids. Thorax 1993; 48: 92-4
53. Fossa SD, Lehne G, Heimdal K, et al. Clinical and biochemical long-term toxicity after postoperative cisplatin-based chemotherapy in patients with low-stage testicular cancer. Oncology 1995; 52: 300-5
54. Vogelzang NJ, Bosl GJ, Johnson K, et al. Raynaud's phenomenon: a common toxicity after combination chemotherapy for testicular cancer. Ann Intern Med 1981; 95: 288-92
55. Vogelzang NJ, Torkelson JL, Kennedy BJ. Hypomagnesemia, renal dysfunction, and Raynaud's phenomenon in patients treated with cisplatin, vinblastine, and bleomycin. Cancer 1985; 56: 2765-70
56. Stoter G, Koopman A, Vendrik CP, et al. Ten-year survival and late sequelae in testicular cancer patients treated with cisplatin, vinblastine, and bleomycin. J Clin Oncol 1989; 7: 1099-104
57. Boyer M, Raghavan D, Harris PJ, et al. Lack of late toxicity in patients treated with cisplatin-containing combination chemotherapy for metastatic testicular cancer. J Clin Oncol 1990; 8: 21-6
58. Meinardi MT, Gietema JA, van Veldhuisen DJ, et al. Treatment related cardiovascular morbidity in long-term survivors of metastatic testicular cancer. J Clin Oncol 2000; 18: 1725-32
59. Bokemeyer C, Berger CC, Kuczyk MA, et al. Evaluation of long-term toxicity after chemotherapy for testicular cancer. J Clin Oncol 1996; 14: 2923-32
60. Adoue D, Arlet P. Bleomycin and Raynaud's phenomenon [letter]. Ann Intern Med 1984; 100: 770
61. Doll D, List A, Greco F, et al. Acute vascular ischemic events after cisplatin-based combination chemotherapy for germ-cell tumors of the testis. Ann Intern Med 1986; 105: 48-51
62. Icli F, Karaoguz H, Dincol D, et al. Severe vascular toxicity associated with cisplatin-based chemotherapy. Cancer 1993; 72: 587-93
63. Rodriguez J, Collazos J, Gallardo M, et al. Angina pectoris following cisplatin, etoposide, and bleomycin in a patient with advanced testicular cancer. Ann Pharmacother 1995; 29: 138-9
64. Samules BL, Vogelzang NJ, Kennedy BJ. Severe vascular toxicity associated with vinblastine, bleomycin, and ciplatin chemotherapy. Cancer Chemother Pharmacol 1987; 19: 253-6
65. Lajer H, Daugaard G. Cisplatin and hypomagnesemia. Cancer Treat Rev 1999; 25: 47-58
66. Turlapaty PD, Altura BM. Magnesium deficiency produces spasms of coronary arteries: relationship to etiology of sudden death ischemic heart disease. Science 1980; 208: 198-200
67. Licciardello JT, Moake JL, Rudy CK, et al. Elevated plasma von Willebrand factor levels and arterial occlusive complications associated with cisplatin-based chemotherapy. Oncology 1985; 42: 296-300
68. Raghavan D, Cox K, Childs A, et al. Hypercholesterolemia after chemotherapy for testis cancer. J Clin Oncol 1992; 10: 1386-9
69. Ellis PA, Fitzharris BM, George PM, et al. Fasting plasma lipid measurements following cisplatin chemotherapy in patients with germ cell tumors. J Clin Oncol 1992; 10: 1609-14
70. Strumberg D, Brugge S, Korn MW, et al. Evaluation of long-term toxicity in patients after cisplatin-based chemotherapy for non-seminomatous testicular cancer. Ann Oncol 2002; 13: 229-36
71. Huddart RA, Shahidi NM, Coward HD, et al. Cardiovascular disease as a long-term complication of treatment for testicular cancer. Cancer J Clin Oncol 2003; 21: 1513-23
72. Lejonc JL, Vernant JP, Macquin J, et al. Myocardial infarction following vinblastine treatment [letter]. Lancet 1980; II: 692
73. Airey C, Dodwell D, Joffe J, et al. Etoposide-related myocardial infarction. Clin Oncol (R Coll Radiol) 1995; 7: 135
74. Thompson SW, Davis LE, Kornfeld M, et al. Cisplatin neuropathy: clinical, electrophysiologic, morphologic, and toxicologic studies. Cancer 1984; 54: 1269-75
75. Hartmann JT, Kollmannsberger C, Kanz L, et al. Platinum organ toxicity and possible prevention in patients with testicular cancer. Int J Cancer 1999; 83: 866-9
76. Hansen SW, Helweg-Larsen S, Trojaborg W. Long-term neurotoxicity in patients treated with cisplatin, vinblastine, and bleomycin for metastatic germ cell cancer. J Clin Oncol 1989; 7: 1457-61
77. Roth BJ, Griest A, Kubilis PS, et al. Cisplatin-based combination chemotherapy for disseminated germ cell tumors: long-term follow-up. J Clin Oncol 1988; 6: 1239-47
78. Van Der Hulst RJ, Dreschler WA, Urbanus NA. High frequency audiometry in prospective clinical research of ototoxicity due to platinum derivatives. Ann Otol Rhinol Laryngol 1988; 97: 133-7
79. Bokemeyer C, Berger CC, Hartmann JT, et al. Analysis of risk factors for cisplatin-induced ototoxicity in patients with testicular cancer. Br J Cancer 1998; 77: 1355-62
80. Gonzales-Vitale JC, Hayes DM, Cvitkovic E, et al. The renal pathology in clinical trials of cis-platinum (II) diamminedichloride. Cancer 1977; 39: 1362-71
81. Dentino M, Luft FC, Yum MN, et al. Long term effect of cisdiamminedichloride platinum (CDDP) on renal function and structure in man. Cancer 1978; 41: 1274-81
82. Fjeldborg P, Sorensen JB, Helkjaer PE, et al. The long-term effect of cisplatin on renal function. Cancer 1986; 58: 2214-7
83. Osanto S, Bukman A, Van Hoek F, et al. Long-term effects of chemotherapy in patients with testicular cancer. J Clin Oncol 1992; 10: 574-9
84. Moul JW, Robertson JE, George SL, et al. Complications of therapy for testicular cancer. J Urol 1989; 142: 1491-6
85. Hartmann JT, Fels LM, Knop S, et al. A randomized trial comparing the nephrotoxicity of cisplatin/ifosfamide-based combination chemotherapy with or without amifostine in patients with solid tumors. Invest New Drugs 2000; 18: 281-9
86. Hartmann JT, von Vangerow A, Fels LM, et al. A randomized trial of amifostine in patients with high-doseVIC chemotherapy plus autologous blood stem cell transplantation. Br J Cancer 2001; 84: 313-20
87. Bajorin DF, Sarosdy MF, Pfister DG, et al. Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumors: a multiinstitutional study. J Clin Oncol 1993; 11: 598-606
88. Horwich A, Sleijfer DT, Fossa SD, et al. Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic non-seminomatous germ cell cancer: a multiinstitutional medical research council/European organization for research and treatment of cancer trial. J Clin Oncol 1997; 15: 1844-52
89. Petersen PM, Skakkebaek NE, Vistisen K, et al. Semen quality and reproductive hormones before orchiectomy in men with testicular cancer. J Clin Oncol 1999; 17: 941-7
90. Turek PJ, Lowther DN, Carroll PR. Fertility issues and their management in men with testis cancer. Urol Clin North Am 1998; 25: 517-31
91. Aass N, Fossa SD, Theodorsen L, et al. Prediction of long term gonadal toxicity after standard treatment for testicular cancer. Eur J Cancer 1991; 27: 1087-91
92. Jacobsen KD, Theodorsen L, Fossa SD. Spermatogenesis after unilateral orchiectomy for testicular cancer in patients following surveillance policy. J Urol 2001; 165: 93-6
93. Boyer M, Raghavan D. Toxicity of treatment of germ cell tumors. Semin Oncol 1992; 19: 128-42
94. de Santis M, Albrecht W, Holtl W, et al. Impact of cytotoxic treatment on long-term fertility in patients with germ-cell cancer. Int J Cancer 1999; 83: 864-5
95. Hansen PV, Hansen SW. Gonadal function in men with testicular germ cell cancer: the influence of cisplatin-based chemotherapy. Eur Urol 1993; 23: 153-6
96. Lampe HH, Nicholls J, Dearnaley DP. Fertility after chemotherapy for testicular germ cell cancers. J Clin Oncol 1997; 15: 239-45
97. Hansen SW, Berthelsen JG, van der Maase H. Long-term fertility and Leydig cell function in patients treated for germ cell cancer with cisplatin, vinblastine, and bleomycin versus surveillance. J Clin Oncol 1990; 8: 1695-8